about
Pseudomonas aeruginosa ventilator-associated pneumonia managementVaccines for Pseudomonas aeruginosa: a long and winding roadDiscovery of an Allosteric Inhibitor Binding Site in 3-Oxo-acyl-ACP Reductase from Pseudomonas aeruginosaProtective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa InfectionDesign of live attenuated bacterial vaccines based on D-glutamate auxotrophy.Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosaImmunogenicity comparison of conjugate vaccines composed of alginate and lipopolysaccharide of Pseudomonas aeruginosa bound to diphtheria toxoid.Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections.X-ray Irradiated Vaccine Confers protection against Pneumonia caused by Pseudomonas aeruginosaMucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infectionBioengineering a bacterial pathogen to assemble its own particulate vaccine capable of inducing cellular immunity.A temporal examination of the planktonic and biofilm proteome of whole cell Pseudomonas aeruginosa PAO1 using quantitative mass spectrometry.Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update.New perspectives in the management of Pseudomonas aeruginosa infections.Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies.Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.Vaccine strategies against cystic fibrosis pathogens.Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.Infection prevention and control guideline for cystic fibrosis: 2013 update.Phytol has antibacterial property by inducing oxidative stress response in Pseudomonas aeruginosa.Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF.40 years on: have we finally got a vaccine for Pseudomonas aeruginosa?Potential targets for next generation anti-microbial glycoconjugate vaccines.Conserved OprF as a Selective Immunogen against Pseudomonas aeruginosa.PA0833 Is an OmpA C-Like Protein That Confers Protection Against Pseudomonas aeruginosa Infection.Induction of Specific Humoral Immune Response in Mice against a Chimeric PilQ/PilA Protein
P2860
Q26768365-20F2F8A4-6BC8-44A3-A434-4EDDEE97170BQ26852817-D4764D0E-A71F-42AD-A6D3-73DC5CFDE6BBQ27679901-D4BD18DD-2D73-491F-91EA-8B05EFE2295AQ33553646-956E36E3-4691-4CEA-9370-298DEA172F8EQ33763029-626DC37F-A3D7-413D-B1AD-7E07D5544E0CQ34599868-D479FCD9-718A-4DA6-93E9-1A82AE4E6FDDQ35270721-639D849B-AAC0-40D2-8376-CACC36A4F197Q36147444-150F9D63-3293-4A72-AFFA-3B9113E576D9Q36583078-2CC3E592-8E3E-46BA-8CEB-86D023B0BA43Q37478266-EADE79B4-55E7-40AE-8E8D-276A783B3AC1Q37620529-552B7F74-ADEB-4BA2-808B-EA3E6200F06CQ37687425-765581E1-8A4D-40FB-99C7-1F36D6BDB94DQ38210319-9AFF150E-D2DD-4099-A800-F1B96994C4DFQ38243221-85A91254-F4F8-41C3-A0F1-3FA43297F2B7Q38599969-2D18EA7D-D7F7-4880-AB3B-49D1F7167101Q38941665-BB202082-D4F6-484A-B786-50A3B5A7DBAEQ40262035-B2296BB3-AC9F-4365-B630-5438043F997BQ40267074-97CBC2DA-E062-480D-AD38-66C5F616C072Q41065563-68BF0B4C-8E14-46FA-B956-2DA23FE800F4Q42206103-19899813-A1B6-4C94-B1FD-93D22816D2F9Q46475798-A738B789-01D1-43B9-8879-156AC10FBFDFQ47415600-1376BDBC-1522-49E8-9836-88930A448DE7Q51053038-98F37A93-EE6A-440B-83CE-CDAEE4205109Q51532849-7EBC9266-24F1-4AD7-8A23-129AC0E39694Q53701548-C7A55283-CEE6-4FC2-B8B4-58748E9268C1Q54260241-03396530-18E3-4E32-A27C-B447C2DD0037Q55222812-E5A50D48-78CA-48FE-B68A-30B4570F5B96Q57489058-D6725A67-1B59-456F-8A04-E5BB2341C206
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recent developments for Pseudomonas vaccines.
@en
Recent developments for Pseudomonas vaccines.
@nl
type
label
Recent developments for Pseudomonas vaccines.
@en
Recent developments for Pseudomonas vaccines.
@nl
prefLabel
Recent developments for Pseudomonas vaccines.
@en
Recent developments for Pseudomonas vaccines.
@nl
P2093
P2860
P356
P1433
P1476
Recent developments for Pseudomonas vaccines.
@en
P2093
Anja Krause
Anurag Sharma
Stefan Worgall
P2860
P304
P356
10.4161/HV.7.10.16369
P577
2011-10-01T00:00:00Z